Overview

Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics

Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This is a prospective, active-controlled, randomized, open label, single-center, multiple dose, two-period crossover clinical trial to assess the efficacy, safety and pharmacokinetics of AQ001S compared to a budesonide inhalation suspension (comparator) in adults with mild asthma. Both treatments will be administered by nebulization.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Aquilon Pharmaceuticals S.A.
Treatments:
Budesonide